广济药业(000952) - 2015 Q1 - 季度财报

Financial Performance - The company's operating revenue for the first quarter was ¥100,300,817.19, representing a 10.03% increase compared to ¥91,156,844.53 in the same period last year[6] - The net profit attributable to shareholders was -¥6,596,515.84, a decrease of 4.68% from -¥6,301,409.37 year-on-year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses improved by 57.20%, amounting to -¥8,038,051.84 compared to -¥18,778,472.85 in the previous year[6] - The net cash flow from operating activities decreased by 131.79%, resulting in -¥54,726,759.45, down from ¥172,147,064.82 in the same period last year[6] - Total assets at the end of the reporting period were ¥1,505,559,939.25, a decrease of 4.86% from ¥1,582,469,533.44 at the end of the previous year[6] - The net assets attributable to shareholders decreased by 1.32%, totaling ¥491,569,479.03 compared to ¥498,165,994.87 at the end of the previous year[6] - The company reported a basic earnings per share of -¥0.026, a decline of 4.00% from -¥0.025 in the same period last year[6] - The weighted average return on net assets was -0.92%, a decrease of 0.04 percentage points from -0.88% year-on-year[6] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 41,769[10] Government Support and Commitments - The company received government subsidies amounting to ¥1,460,400.00 during the reporting period[8] - The company is currently fulfilling commitments made during the share transfer, including providing at least 300 million yuan in loans to Guangji Pharmaceutical with a term of no less than 3 years[17] - The company has committed to ensuring that the audited net profit for the fiscal years 2015 to 2017 will be positive, with any shortfall to be compensated in cash[17] Strategic Development - The company plans to support Guangji Pharmaceutical's development strategy and goals, focusing on existing businesses and products while introducing new products[18] - The company is actively working to resolve current constraints on Guangji Pharmaceutical's development and promote the subsequent development of the biological industry park[18] - The company has committed to improving the management team's and employees' compensation to enhance the continuous development of the listed company[18] Future Expectations - There are no significant changes expected in the cumulative net profit for the first half of 2015 compared to the previous year[19] Investment Activities - The company did not engage in any securities investments during the reporting period[20] - The company did not hold any equity in other listed companies during the reporting period[20] - There were no derivative investments made by the company during the reporting period[21] - The company did not conduct any research, communication, or interview activities during the reporting period[22]